WO2001011063A3 - Kombinationsvektoren für den gentransfer, verfahren zu ihrer herstellung und ihre verwendung - Google Patents

Kombinationsvektoren für den gentransfer, verfahren zu ihrer herstellung und ihre verwendung Download PDF

Info

Publication number
WO2001011063A3
WO2001011063A3 PCT/DE2000/002726 DE0002726W WO0111063A3 WO 2001011063 A3 WO2001011063 A3 WO 2001011063A3 DE 0002726 W DE0002726 W DE 0002726W WO 0111063 A3 WO0111063 A3 WO 0111063A3
Authority
WO
WIPO (PCT)
Prior art keywords
utilization
production
gene transfer
combination vectors
transfer combination
Prior art date
Application number
PCT/DE2000/002726
Other languages
English (en)
French (fr)
Other versions
WO2001011063A2 (de
Inventor
Frank Tiemann
Original Assignee
Develogen Ag
Frank Tiemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag, Frank Tiemann filed Critical Develogen Ag
Priority to AU77698/00A priority Critical patent/AU7769800A/en
Publication of WO2001011063A2 publication Critical patent/WO2001011063A2/de
Publication of WO2001011063A3 publication Critical patent/WO2001011063A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Die Erfindung betrifft neue Kombinationsvektoren für den Gentransfer, die aus einem einzelnen DNA-Molekül bestehen, das mehrere exprimierbare Gene umfaßt. Desweiteren betrifft die Erfindung Verfahren zur Herstellung dieser Kombinationsvektoren und ihre Verwendung zur Therapie maligner Erkrankungen und anderer Hyperplasien. Anwendungsgebiete sind die Medizin und die pharmazeutische Industrie.
PCT/DE2000/002726 1999-08-10 2000-08-10 Kombinationsvektoren für den gentransfer, verfahren zu ihrer herstellung und ihre verwendung WO2001011063A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU77698/00A AU7769800A (en) 1999-08-10 2000-08-10 Gene transfer combination vectors, method for the production and utilization thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19937308 1999-08-10
DE19937308.6 1999-08-10

Publications (2)

Publication Number Publication Date
WO2001011063A2 WO2001011063A2 (de) 2001-02-15
WO2001011063A3 true WO2001011063A3 (de) 2001-11-22

Family

ID=7917553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/002726 WO2001011063A2 (de) 1999-08-10 2000-08-10 Kombinationsvektoren für den gentransfer, verfahren zu ihrer herstellung und ihre verwendung

Country Status (3)

Country Link
AU (1) AU7769800A (de)
DE (1) DE10039844A1 (de)
WO (1) WO2001011063A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10159128A1 (de) * 2001-07-13 2003-01-23 Karsten Brand Genregulatorische Elemente zur Gentherapie, zur Prävention und Diagnose von Metastasen bzw. zur Gentherapie von Tumoren
EP1766002B1 (de) 2004-06-21 2015-11-18 Novozymes A/S Mehrere kopien wenigstens zweier offener leserrahmen stabil erhalten in gleicher orientierung

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005786A1 (de) * 1992-08-27 1994-03-17 Beiersdorf Ag Herstellung von heterodimerem pdgf-ab mit hilfe eines bicistronischen vektorsystems in säugerzellen
WO1996024669A1 (en) * 1995-02-10 1996-08-15 The Regents Of The University Of California Human pancreatic cell lines: developments and uses
WO1998022606A1 (fr) * 1996-11-15 1998-05-28 Rhone-Poulenc Rorer S.A. Adenovirus recombinants bicistroniques pour le traitement de pathologies liees aux dyslipoproteinemies
EP0859058A2 (de) * 1997-01-16 1998-08-19 Hoechst Aktiengesellschaft Nukleinsäurekonstrukt zur Expression von durch Proteasen aktivierbare Wirksubstanzen, sowie Herstellung und Verwendung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005786A1 (de) * 1992-08-27 1994-03-17 Beiersdorf Ag Herstellung von heterodimerem pdgf-ab mit hilfe eines bicistronischen vektorsystems in säugerzellen
WO1996024669A1 (en) * 1995-02-10 1996-08-15 The Regents Of The University Of California Human pancreatic cell lines: developments and uses
WO1998022606A1 (fr) * 1996-11-15 1998-05-28 Rhone-Poulenc Rorer S.A. Adenovirus recombinants bicistroniques pour le traitement de pathologies liees aux dyslipoproteinemies
EP0859058A2 (de) * 1997-01-16 1998-08-19 Hoechst Aktiengesellschaft Nukleinsäurekonstrukt zur Expression von durch Proteasen aktivierbare Wirksubstanzen, sowie Herstellung und Verwendung

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DANG C.V & LEE W.M.F.: "Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc. p53, HSP70 and HIV-tat proteins", J. BIOL. CHEM., vol. 264, no. 30, 25 October 1989 (1989-10-25), pages 18019 - 18023, XP002164452 *
FUJIMOTO K. ET AL.: "Inhibition of pRB phosphorylation and cell cycle progression by an antennapedia-p16/INK4 fusion peptide in pancreatic cancer cells.", GASTROENTEROLOGY, vol. 116, April 1999 (1999-04-01), pages A407, XP000990822 *
KYRITSIS A.P. ET AL.: "A bicistronic recombinant adenovirus carrying both p53 and p16 tumor suppressor genes for treatment of p53-resistant gliomas.", NEUROLOGY, vol. 50, April 1998 (1998-04-01), pages A272, XP000990751 *
PHELAN A. ET AL: "Intercellular delivery of functional p53 by the herpesvirus protein VP22", NATURE BIOTECHNOLOGY,NATURE PUBLISHING,US, vol. 16, 1998, pages 440 - 443, XP000979081, ISSN: 1087-0156 *
SANDIG V ET AL: "ADENOVIRALLY TRANSFERRED P16INK4/CDKN2 AND P53 GENES COOPERATE TO INDUCE APOPTOTIC TUMOR CELL DEATH", NATURE MEDICINE,US,NATURE PUBLISHING, CO, vol. 3, no. 3, 1 March 1997 (1997-03-01), pages 313 - 319, XP002037359, ISSN: 1078-8956 *
STOTT F.J. ET AL.: "The alternative product from the human CDKN2A locus, p14/ARF, participates in a regulatory feedback loop with p53 and MDM2.", EMBO J., vol. 17, no. 17, 1998, pages 5001 - 5014, XP002164451 *
TIEMANN F. ET AL.: "Efficacy and safety of p53/p16 adenovirus-mediated gene therapy for the treatment of hepatocellular carcinoma.", PROC. AMER. ASSN. CANCER RES. ANNUAL MEETING, March 2000 (2000-03-01), pages 121, XP000990707 *

Also Published As

Publication number Publication date
WO2001011063A2 (de) 2001-02-15
AU7769800A (en) 2001-03-05
DE10039844A1 (de) 2001-04-19

Similar Documents

Publication Publication Date Title
MX9706109A (es) Moleculas de adn, preparacion y utilizacion en terapia genica.
WO2001002568A3 (en) Human genes and gene expression products
WO2001012659A3 (en) Human dna sequences
WO2001030965A3 (en) Methods of in vivo gene transfer using a sleeping beauty transposon system
EP2280030A3 (de) Nukleinsäuren und zugehörige Proteine für die Behandlung und den Nachweis von Krebs
KR970700771A (ko) 비-바이러스 벡터(Non-viral vector)
HK1004110A1 (en) Transfer of molecules into the cytosol of cells
AU4077100A (en) Enhancement of the immune response for vaccine and gene therapy applications
MXPA03002413A (es) Moleculas tipo b7 y uso de las mismas.
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
WO2001083774A3 (en) Novel mutated form of arginine deiminase
ATE384118T1 (de) Gene von felincalizivirus und impstoffe, die diese gene enthalten
WO1995034669A3 (en) Retroviral gene therapy vectors and therapeutic methods based thereon
CA2495529A1 (en) Noonan syndrome gene
WO2001011063A3 (de) Kombinationsvektoren für den gentransfer, verfahren zu ihrer herstellung und ihre verwendung
WO1999053087A3 (de) 5'-modifizierte nukleotide und ihre anwendung in der molekularbiologie und medizin
NZ324157A (en) Conditionally replicating viral vectors and their use in treating HIV
WO2001048208A3 (en) Streptococcus pyogenes virulence genes and proteins and their use
AU6113098A (en) Compositions for treatment of disorders involving programmed cell death
AU3762699A (en) (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
WO2001014415A3 (en) Egfh2 genes and gene products
AU5455798A (en) Gene product over expressed in cancer cells
HUP0300813A2 (hu) Gének, fehérjék és alkalmazásuk
WO2001009173A3 (fr) Utilisation des acides quinique, shikimique et de leurs derives pour la preparation de ligands du recepteur du mannose
WO2002010203A3 (en) Daz genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP